Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of lacosamide for uncontrolled primary generalized tonic-clonic seizures in idiopathic generalized epilepsy
2012-001770-29Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lacosamide in idiopathic epilepsy (IGE) and generalized tonic-clonic seizure (GTCS), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Started Apr 2015; status: completed.
02
Drugs
lacosamide
03
Conditions
idiopathic epilepsy (IGE)generalized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2012-001770-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001770-29.